Elevance Health Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Gail Boudreaux

Algemeen directeur

US$21.9m

Totale compensatie

Percentage CEO-salaris	7.3%
Dienstverband CEO	7yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	11.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Gail Boudreaux's beloning veranderd ten opzichte van Elevance Health's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$22m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$17m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$5b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$15m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$4b
Dec 31 2018	US$14m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$5b
Jun 30 2018	n/a	n/a	US$4b
Mar 31 2018	n/a	n/a	US$4b
Dec 31 2017	US$3m	US$162k	US$4b

Compensatie versus markt: De totale vergoeding ($USD 21.89M ) Gail } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 5.75M ).

Compensatie versus inkomsten: De vergoeding van Gail is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Gail Boudreaux (63 yo)

7yrs

Tenure

US$21,889,039

Compensatie

Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gail Boudreaux	President	7yrs	US$21.89m	0.047% MX$ 906.9m
Mark Kaye	Executive VP & CFO	less than a year	US$12.36m	0.0017% MX$ 32.5m
Blair Todt	Executive VP and Chief Legal & Administrative Officer	4yrs	US$8.11m	0.0044% MX$ 84.9m
Peter Haytaian	Executive VP and President of Carelon & CarelonRx	10.4yrs	US$6.98m	0.0071% MX$ 135.0m
Felicia Norwood	Executive VP & President of Government Health Benefits	6.4yrs	US$6.48m	0.0098% MX$ 186.6m
Scott Anglin	SVP, Treasurer & Chief Investment Officer	6.6yrs	geen gegevens	geen gegevens
Ronald Penczek	Senior VP	9yrs	geen gegevens	0.00057% MX$ 10.9m
Stephen Tanal	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Julie Goon	Senior Vice President of Public Affairs	11yrs	geen gegevens	geen gegevens
Kyle Weber	Chief Strategy Officer & Interim Chief Marketing Officer	less than a year	geen gegevens	geen gegevens
Charles Kendrick	Executive VP & President of Commercial Health Benefits	no data	geen gegevens	0.0022% MX$ 42.3m
Scott Towers	President of Dental Business	8yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ELV * is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gail Boudreaux	President	7yrs	US$21.89m	0.047% MX$ 906.9m
Ramiro Peru	Independent Director	20yrs	US$386.76k	0.0024% MX$ 45.5m
Elizabeth Tallett	Independent Chair of the Board	11.1yrs	US$597.83k	geen gegevens
Lewis Hay	Independent Director	11.3yrs	US$362.53k	geen gegevens
Bahija Jallal	Independent Director	6.8yrs	US$371.42k	geen gegevens
Ronal Clark	Independent Director	10.5yrs	US$371.42k	geen gegevens
Ryan Schneider	Independent Director	5.1yrs	US$347.28k	0.0013% MX$ 24.7m
Robert Dixon	Independent Director	13.3yrs	US$360.34k	0.0031% MX$ 59.7m
Heath Gilbert	Member of Advisory Board	11.3yrs	geen gegevens	geen gegevens
Douglas Kiefer	Member of Advisory Board	11.3yrs	geen gegevens	geen gegevens
Karin Meng	Member of Advisory Board	11.3yrs	geen gegevens	geen gegevens
Steven Richlin	Member of Advisory Board	11.3yrs	geen gegevens	geen gegevens

11.3yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ELV * zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.3 jaar).

Elevance Health Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Director recently sold Mex$2.8m worth of stock

Insufficient new directors

Insufficient new directors

Insider recently sold Mex$117m worth of stock

Insufficient new directors

Senior VP recently sold Mex$7.8m worth of stock

Recent updates

Third quarter dividend of US$1.63 announced

Elevance Health, Inc. (NYSE:ELV) agreed to acquire CareBridge Medical Group, P.C.

Third quarter 2024 earnings released: EPS: US$4.36 (vs US$5.48 in 3Q 2023)

Elevance Health, Inc. Declares Dividend for the Fourth Quarter of 2024, Payable on December 20, 2024

Las Mercedes Medical Centers acquired Pasteur and Wellmax Medical Centers from Elevance Health, Inc. (NYSE:ELV).

Elevance Health, Inc. to Report Q3, 2024 Results on Oct 17, 2024

Upcoming dividend of US$1.63 per share

Clayton, Dubilier & Rice and Elevance Health Announces the Introduction of Mosaic Health, a National Care Delivery Platform

Independent Director recently sold Mex$2.8m worth of stock

Second quarter dividend of US$1.63 announced

Elevance Health, Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 25, 2024

Elevance Health, Inc. to Report Q2, 2024 Results on Jul 17, 2024

Insufficient new directors

Upcoming dividend of US$1.63 per share

Insufficient new directors

Insider recently sold Mex$117m worth of stock

First quarter dividend of US$1.63 announced

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2024

Insufficient new directors

Elevance Health, Inc. to Report Q1, 2024 Results on Apr 18, 2024

StanCorp Financial Group, Inc. completed the acquisition of Life & Disability business of Elevance Health, Inc.

StanCorp Financial Group, Inc. completed the acquisition of Life & Disability business of Elevance Health, Inc.

Senior VP recently sold Mex$7.8m worth of stock

Insufficient new directors

Upcoming dividend of US$1.63 per share

Full year 2023 earnings released: EPS: US$25.38 (vs US$24.56 in FY 2022)

Elevance Health, Inc., Annual General Meeting, May 15, 2024

Insufficient new directors

Elevance Health, Inc. Declares Quarterly Cash Dividend, Payable on March 22, 2024

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2024

Elevance Health, Inc. to Report Q4, 2023 Results on Jan 24, 2024

Elevance Health Addresses Healthcare’S Digital Divide by Increasing Access to High-Quality Smartphones and Health-Related Digital Services

Senior VP recently sold Mex$8.7m worth of stock

Insufficient new directors

Third quarter 2023 earnings released: EPS: US$5.48 (vs US$6.75 in 3Q 2022)

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2023

Elevance Health, Inc. to Report Q3, 2023 Results on Oct 18, 2023

Insufficient new directors

Upcoming dividend of US$1.48 per share at 1.3% yield

Insufficient new directors

Elevance Health, Inc. Announces Executive Changes

Independent Director recently sold Mex$2.5m worth of stock

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$7.79 (vs US$6.87 in 2Q 2022)

Elevance Health, Inc. to Report Q2, 2023 Results on Jul 19, 2023

Upcoming dividend of US$1.48 per share at 1.3% yield

First quarter 2023 earnings released: EPS: US$8.30 (vs US$7.48 in 1Q 2022)

Insufficient new directors

Upcoming dividend of US$1.48 per share at 1.3% yield

Elevance Health, Inc., Annual General Meeting, May 10, 2023

Elevance Health Inc. (NYSE:ELV) completed the acquisition of BioPlus Specialty Pharmacy Services, LLC from CarepathRx.

Full year 2022 earnings released: EPS: US$24.82 (vs US$25.04 in FY 2021)

Elevance Health Inc. Provides Earnings Guidance for the Fiscal Year 2023

Elevance Health Inc. (NYSE:ELV) entered into a definitive agreement Louisiana Health Service and Indemnity Company.

Elevance Health Inc. to Report Q4, 2022 Results on Jan 25, 2023

Insufficient new directors

Insufficient new directors

Upcoming dividend of US$1.28 per share

Insufficient new directors

Elevance Health Inc. (NYSE:ELV) entered into an agreement to acquire BioPlus Specialty Pharmacy Services, LLC from CarepathRx.

Elevance Health, Inc. Appoints Deanna Strable-Soethout as an Independent Director, Effective November 1, 2022

Elevance Health Inc. Provides Earnings Guidance for Full Year 2022

Elevance Health Inc. to Report Q3, 2022 Results on Oct 19, 2022

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released

Elevance Health Inc. Declares Third Quarter 2022 Dividend, Payable on September 23, 2022

Elevance Health Inc. to Report Q2, 2022 Results on Jul 20, 2022